Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00268905 · ClinicalTrials.gov registry record · Phase 1
A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT00268905 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 64 participants.
The verdict
NCT00268905, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and to explore the safety and anti-tumor activity of E7389 in combination with carboplatin in patients with advanced solid tumors.
Interventions
- DRUG E7389 + carboplatin AUC 5
- DRUG E7389 + carboplatin AUC 6
- DRUG E7389+carboplatin AUC 6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00268905
The ClinicalTrials.gov registry entry for NCT00268905 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which E7389 + carboplatin AUC 5 is the first listed.
NCT00268905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00268905 about?
NCT00268905 is a clinical study titled "A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors". The purpose of this study is to determine the maximum tolerated dose (MTD) and to explore the safety and anti-tumor activity of E7389 in combination with carboplatin in patients with advanced solid tumors.
What is the current status of trial NCT00268905?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2006-10.
What interventions are being tested in trial NCT00268905?
The interventions under investigation include: E7389 + carboplatin AUC 5 (DRUG), E7389 + carboplatin AUC 6 (DRUG), E7389+carboplatin AUC 6 (DRUG).
Who is sponsoring clinical trial NCT00268905?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.